Altre lingue Immunovia AB

Azioni

IMMNOV

SE0006091997

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:07:43 18/04/2024			Variaz. 5gg	Var. 1 gen.
1,788 ^SEK	+1,94%		-1,76%	+0,90%

09/04	Immunovia, Proteomedix creano saggi per il test di rilevamento del cancro al pancreas	MT
09/04	Immunovia ha sviluppato con successo dei saggi per misurare le proteine mirate per il suo test di prossima generazione sul cancro al pancreas - Procedendo verso lo studio di sviluppo del modello	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	09/04
Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study	09/04
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study	09/04
Immunovia announces updated financial calendar	12/03
Immunovia Publishes Full Year Report for 2023	21/02
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Invitation to Immunovia's Q4 presentation	14/02
Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs	31/01
Immunovia announces financial calendar for financial year 2024	04/01
Immunovia AB Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members	21/11
Bulletin from the extraordinary general meeting in Immunovia AB	21/11
Immunovia Publishes Interim Report for January-September 2023	09/11
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Immunovia Shares Surge on Discovery Study for New Pancreatic Cancer Test	07/11
Immunovia successfully completes discovery phase of next-generation test development	07/11
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	07/11
Bilaga: Villkor för teckningsoptioner serie 2023:2034:1	02/11
Bilaga: Villkor för teckningsoptioner serie 2023:2034:2	02/11
Appendix: Immunovia AB (PUBL) long term incentive plan for Unites States residents	02/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Immunovia AB

Azioni

IMMNOV

SE0006091997

Altre lingue

Filtri